User:Patriciagonzalezdias/sandbox

Daniela M. Ferreira is a Brazilian British immunologist. She is a global leader in Human Infection Challenge with experience in bacterial challenge, respiratory co-infection, mucosal immunology and vaccine responses. She is currently the Head of Clinical Sciences Department and Professor of respiratory vaccines and infection immunology at Liverpool School of Tropical Medicine. She leads a team of scientists studying protective immune responses against pneumococcus  and other respiratory pathogens such as SARS-CoV2. Her team has established a novel method of inducing pneumococcal carriage in human volunteers. . They use this model to:
 * Discover how people with risk factors (age, chronic lung disease) make responses to respiratory bacteria and virus and how this is different from healthy people
 * Pre-select vaccine candidates and test new vaccines more rapidly
 * Discover how the host alters the biology of the bacteria while it is being carried

Her team has played a substantial role in the UK covid-19 pandemic response as a trial site for several COVID-19 vaccine studies including the Oxford / Astrazeneca vaccine.

Ferreira is part of the HIC-VACc onsortium and Leads the WorkStream on Human Challenge Plataform to accelerate product development in the UKRI Infection Innovation Consortium (iicon).

Research and career
Ferreira obtained a Degree and Bachelor's Degree in Biological Sciences in 2005 and a Ph.D. in Immunology in 2009, both from the University of São Paulo (São Paulo, Brazil). During her PhD, Ferreira was awarded the  Robert Austrian Research Award in Pneumococcal Vaccinology.

Ferreira joined the Respiratory Infection group at Liverpool School of Tropical Medicine as a postdoctoral fellow in December 2009 and together with Prof Stephen Gordon led the development of an Experimental Human Pneumococcal Nasopharyngeal Colonization Model. Ferreira was appointed Professor and subsequent Head of Department of Clinical Sciences in 2018. In particular, her main lines of research are:
 * 1) Accelerate development and test novel pneumococcal vaccines using experimental carriage
 * 2) Understanding nasal and lung immune responses and correlates of protection against respiratory infection with viruses including SARS-CoV2 and bacteria
 * 3) Defining how respiratory virus co-infections (flu, RSV and SARS-CoV2) and host susceptibility (asthma, COPD, aging, smoke) alters responses to pneumococcal infection

Key Publications

 * Steenhuijsen Piters WAA, Jochems S, Mitsi E, Rylance J, Pojar S, Nikolaou E, German EL, Holloway M, Carniel BF, Chu MLJN, Arp K,. Sanders EAM, Ferreira DM* and Bogaert D.* Interaction between live-attenuated influenza vaccine, Streptococcus pneumoniae and the nasal microbiota. Nat Commun. 10, 2981 (2019), https://doi.org/10.1038/s41467-019-10814-9.
 * Jochems SP, Marcon F, Carniel BF, Zaidi S, Piddock K, Wheeler I, Gordon SB, Rylance J, Nakaya H, Ferreira DM. Inflammation induced by influenza virus impairs innate control of human pneumococcal carriage. Nature Immunology. 2018 Dec;19(12):1299-1308. doi: 10.1038/s41590-018-0231-y. Epub 2018 Oct 29.